Collectively, these results highlight the ability of Flt3L to mobilize immature DCs and of NDV-killed tumor cells to both load these DCs with tumor Ag and activate them to potentiate cross-priming of tumor-reactive CD8+ T cells. Here, FLT3LG is linked to neoplasm.